Photocure ASA: Transactions made under share buyback program

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets. For the period from and including 19 December 2024, through 3 January 2024, the Company purchased a total of 150,802 shares at an average price of NOK 62.43 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview: Date Aggregated daily Weighted average Total daily volume (#shares) share price per day transaction value (NOK) (NOK) 19.12.2024 23,776 61.43 1,460,610 20.12.2024 21,764 62.95 1,370,150 23.12.2024 21,170 64.17 1,358,511 27.12.2024 16,547 64.29 1,063,742 30.12.2024 21,564 63.50 1,369,286 02.02.2025 22,401 61.77 1,383,629 03.01.2025 23,580 59.73 1,408,325 Total for #shares Weighted average Total transaction the period share price (NOK value (NOK) 150,802 62.43 9,414,253 No previously disclosed buybacks under the program. Accumulated under #shares Weighted average Total transaction value (NOK) the buyback share price (NOK program 150,802 62.43 9,414,253 The issuer's holding of own shares: Following the completion of the above transactions, Photocure owns a total of 165,924 of own shares (including 15,122 shares owned prior to the launch of the buyback program), corresponding to 0.61% of Photocure's share capital. Appendix: An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no. For further information, please contact: Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: ed@photocure.com About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com and www.cysview.com. All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This information is made public by Photocure ASA pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.